

#2
4/9/02
SN

MAR 2 2002
PTO
TRADE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF: Lam et al : **CASE NO.:** DM-6904-A
SERIAL NO.: 09/924,381 : **ART UNIT:** 1624
FILED: August 8, 2001 : **EXAMINER:** UNKNOWN
FOR: NOVEL GUANIDINE MIMICS AS FACTOR XA INHIBITORS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below.
- () The fee of \$240.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1)


Please charge any deficiency or credit any overpayment to Deposit Account No. 02-3850. There are no listed references which are not in the English language.

Respectfully submitted,

Jing S. Belfield ✓

Jing S. Belfield
Agent for Applicants
Registration No. 45,914
Telephone: 302-695-1718

DATE: 3/13/2002
Bristol-Myers Squibb Pharma Company
P. O. Box 4000
Princeton, NJ 08543-4000



1624

PTO/SB/92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

IN THE APPLICATION OF: Lam et al : CASE NO.: DM-6904-A
SERIAL NO.: 09/924,381 : ART UNIT: 1624
FILED: August 8, 2001 : EXAMINER: UNKNOWN
FOR: NOVEL GUANIDINE MIMICS AS FACTOR XA INHIBITORS

I hereby certify that this correspondence a **Information Disclosure Statement, PTO Form 1449, References and a postcard** are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 01 2002

On 3-14-02
Date

TECH CENTER 1600/2900

Diane C Pickering
Signature

Diane C. Pickering/Depositor
Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.